Chinook Therapeutics, Inc.

Quick facts

Phase 3 pipeline

• BION-1301 · Oncology
  BION-1301 is a monoclonal antibody that targets and inhibits FGFR4 (fibroblast growth factor receptor 4) to reduce hepatocellular carcinoma cell growth and survival.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Chinook Therapeutics, Inc. portfolio CI brief
• Chinook Therapeutics, Inc. pipeline updates RSS